陈罡

双博士，教授，硕士研究生导师

办公电话：0771-5352194

邮箱：[email protected]

工作单位：广西医科大学第一附属医院病理科，广西医科大学基因组与个体化医学研究中心

个人简历：

      2007 年获广西医科大学病理学博士学位；2012 年获比利时布鲁塞尔自由大学分子肿瘤学博士学位。长期从事分子病理诊断、肿瘤分子病理学及肿瘤基因治疗的研究工作。中国抗癌协会肿瘤病理专业青年委员会委员。目前正主持“国家自然科学基金”、“广西自然科学基金项目立项”各一项，并曾主要承担比利时布鲁塞尔自由大学的多项国际合作课题的研究工作，主要方向为恶性肿瘤发病分子机制及个体化分子靶向治疗。近年来作为主要参加者，还先后合作参加国家自然科学基金项目、国家教育部、广西区卫生厅、广西区科技厅科研课题等多个项目。在国内外杂志发表论文200余篇，其中以第一/共同第一作者/共同通讯作者发表SCI论文35篇，单篇最高影响因子7.276分，被引用共130次。曾多次赴法国、荷兰、德国、西班牙、意大利等国家参加国际学术会议。

主持或参加的科研项目：

      1. 国家自然科学基金地区基金项目，项目任务书编号：81360327，miR-146a靶向IRAK1与TRAF6调控非小细胞肺癌转移的机制研究，2014/01-2017/12，50万元，在研，主持。

      2. 广西自然科学基金项目，项目任务书编号：2013GXNSFAA019157，EV71 受体PSGL-1, SCARB2 及miR-143 在手足口病中作用机制的研究，2013/04-2016/03，5万元，在研，主持。

      3. 广西自然科学基金青年基金项目，项目任务书编号：2010GXNSFB013059，靶向DcR3 微小RNA 表达谱的鉴定及对肝癌的生物学作用研究，2010/04-2013/03,5万元，已结题，主持。

      4. National Cancer Plan Belgium （The Stichting Tegen Kanker ）, 比利时国家肿瘤研究项目，项目任务书编号：Grant NKP-29-01，Functional analysis of HER pathways, inhibition, and mechanisms of resistance in lung cancer，2009/01-2012/01,50万欧元，已结题，参加。

      5. Belgium International Cancer Fund比利时国际合作项目，项目任务书编号：Grant-25-057，Treatment of non-small cell lung cancer by nanobody-small interference RNA complexes，2008/01-2012/12,50万欧元，已结题，参加。

      6. 广西自然科学基金项目，项目任务书编号：2011GXNSFA018212，Mas癌基因在鼻咽癌的表达及作用机制的研究，2011/04-2015/03，5万元，在研，参加。

      7. 广西科学研究与技术开发计划项目，项目任务书编号：桂科攻10124001A-33，广西早期宫颈癌及癌前病变筛查模式的建立及推广应用与示范，2010-2012，7万元，已结题，参加。

      8. 国家自然科学基金地区基金项目，项目任务书编号：30960345，H9N2流感病毒感染体外人肺组织后的基因变化，2009-2012，50万元，已结题，参加。

所获奖励：

      1) 2006年 获中国留学基金委CSC-比利时布鲁塞尔自由大学VUB博士留学奖学金。

      2) 2008年 获广西医药卫生适宜技术推广奖 三等奖 “survivin、Fas、FasL及ERK1/2、JNK和p38基因在实验性大鼠肝癌形成过程中的作用研究” （冯震博、苏建家、曹骥、欧超、李瑗、陈茂伟、岳惠芬、杨春、段小娴、陈罡、曾丽霞、陈远能、韦薇）

科研成果：（近年来已发表主要论著，第一作者以#标出，通讯作者以*标出）

1. Pan LJ#, Zhong TF#, Tang RX, Li P, Dang YW, Huang SN, Chen G*. Upregulation and Clinicopathological Significance of Long Non-coding NEAT1 RNA in NSCLC Tissues. Asian Pac J Cancer Prev. 2015;16(7):2851-5. 2. Lan D#, Zhang X#, He R, Tang R, Li P, He Q, Chen G*. MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance. Eur J Med Res. 2015 Apr 23;20(1):50. 3. Pan D, Wei K, Ling Y, Su S, Zhu M, Chen G*. The Prognostic Role of Ki-67/MIB-1 in Cervical Cancer: A Systematic Review with Meta-Analysis. Med Sci Monit. 2015 Mar 25;21:882-9. 4. Gan TQ#, Tang RX#, He RQ, Dang YW, Xie Y, Chen G*. Upregulated MiR-1269 in hepatocellular carcinoma and its clinical significance. Int J Clin Exp Med. 2015 Jan 15;8(1):714-21. 5. Pan L#, Ren F#, Rong M, Dang Y, Luo Y, Luo D, Chen G*. Correlation between down-expression of miR-431 and clinicopathological significance in HCC tissues. Clin Transl Oncol. 2015 Mar 17. [Epub ahead of print] PubMed PMID: 25775917. 6. Zhang X#, Li P#, Rong M, He R, Hou X, Xie Y, Chen G*. MicroRNA-141 Is a Biomarker for Progression of Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Clinical Analysis of 125 Patients. Tohoku J Exp Med. 2015;235(3):161-9. doi: 10.1620/tjem.235.161. PubMed PMID: 25746592. 7. Zhang XL, Wei KL, Dang YW, Xie Y, Zhong TF, Ma Y, Chen G*. Primary urinary bladder adenosquamous carcinoma complicated with lower limb deep venous thromboses: a case report. Int J Clin Exp Pathol. 2014;7(12):9032-7. 8. Chen WJ, He DS, Tang RX, Ren FH, Chen G*. Ki-67 is a Valuable Prognostic Factor in Gliomas: Evidence from a Systematic Review and Meta-analysis. Asian Pac J Cancer Prev. 2015;16(2):411-20. 9. Huang L, Ren F, Tang R, Feng Z, Chen G*. Prognostic Value of Expression of Cyclin E in Gastrointestinal Cancer: A Systematic Review and Meta-Analysis. Technol Cancer Res Treat. 2015 Jan 26. pii: 1533034614568098. [Epub ahead of print] PubMed PMID: 25627202. 10. Zhang XL, Dang YW, Li P, Rong MH, Hou XX, Luo DZ, Chen G*. Expression of Tumor Necrosis Factor Receptor-associated Factor 6 in Lung Cancer Tissues. Asian Pac J Cancer Prev. 2014;15(24):10591-6.  11. Zhang X#, Dang Y#, Li P, Rong M, Chen G*. Expression of IRAK1 in lung cancer tissues and its clinicopathological significance: a microarray study. Int J Clin Exp Pathol. 2014 Oct 15;7(11):8096-104. 12. Jiang YQ#, Zhong TF#, Dang YW, Zou LS, Yang L, Yang X, Chen G*. Overexpression and clinicopathological contribution of DcR3 in bladder urothelial carcinoma tissues. Asian Pac J Cancer Prev. 2014;15(21):9137-42. 13. Pan L#, Huang S#, He R, Rong M, Dang Y, Chen G*. Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues. Eur J Med Res. 2014 Dec 2;19(1):68. 14. Wang L, Dang Y, He R, Chen G*. Rare cavernous hemangioma of adrenal gland：case report. sao paulo med j . 2014, 132（4）：249-252. 15. Dang YW#, Zeng J#, HE RQ, Ron MH, Chen G*. Effect of miR-152 on Cell Growth Inhibition, Motility Suppression and Apoptosis Induction in Hepatocellular Carcinoma Cells. Asian Pac J Cancer Prev. 2014;15(12):4969-4976. 16. Huang S#, He R#, Rong M, Dang Y, Chen G. * Synergistic Effect of MiR-146a Mimic and Cetuximab on Hepatocellular Carcinoma Cells; BioMed Research International（formerly titled Journal of Biomedicine and Biotechnology）;2014:384121. 17. Huang S #, Chen G #, Dang Y, Chen LH*. Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma. The Scientific World Journal;2014:605236. 18. Liu J. H. #, Chen G. #, Dang Y. W., Li C. J., Luo D. Z. Expression and Prognostic Significance of lncRNA MALAT1 in Pancreatic Cancer Tissues. Asian Pacific journal of cancer prevention : APJCP;2014;15(7):2971-2977. 19. Rong M#, He R#, Dang Y., Chen G.* Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Upsala journal of medical sciences;2014;119(1):19-24. 20. Chen G. #, Noor A#, Kronenberger P., Teugels E., Umelo I. A., De Greve J*. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PloS one;2013;8(3):e59708. 21. Chen G. #, Umelo I. A#, Lv S., Teugels E., Fostier K., Kronenberger P., Dewaele A., Sadones J., Geers C., De Greve J*. miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PloS one;2013;8(3):e60317. 22. Dang Y., Luo D., Rong M., Chen G. * Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PloS one; 2013; 8(4): e61054. 23. Rong M. #, Chen G. #, Dang Y. Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC cancer;2013;13:21. 24. Chen G. #, Kronenberger P., Teugels E., Umelo I. A., De Greve J*. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochemical and biophysical research communications; 2013;431(3):623-629. 25. Rong M. H., Dang Y. W., Chen G. * Lack of significant association between plasma/serum miR-221 expression and poor survival of carcinoma: a meta-analysis. The Scientific World Journal;2013:394030. 26. Chen G.#, Kronenberger P., Teugels E., Umelo I. A., De Greve J*. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC medicine;2012;10:28. 27. Chen G. #, Kronenberger P., Teugels E., De Greve J*. Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. Biological procedures online;2011;13:1. 28. Hu L. #, Chen G. #, Yu H., Qiu X*. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatology international;2010;4(1):423-432. 29. Chen G. #, Kronenberger P., Umelo I. A., Teugels E., De Greve J*. Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Analytical biochemistry;2010;398(2):266-268. 30. Yang M. #, Chen G. #, Dang Y., Luo D*. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Upsala journal of medical sciences; 2010;115(4):232-237. 31. Chen G. #, Rong M., Luo D*. TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathology, research and practice;2010;206(9):631-641. 32. Chen G. #, Luo D*. Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Upsala journal of medical sciences; 2008; 113(3):297-304. 33. Chen G. #, Dang Y. W., Luo D. Z*., Feng Z. B., Tang X. L. Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. Oncology research;2008;17(4):183-189. 34. Chen G. #, Luo D*. Expression of decoy receptor 3 in liver tissue microarrays. The National medical journal of India;2008;21(6):275-278. 35. Chen G #, Luo DZ*., Liu L, Feng ZB., Guo F, Li P. Hepatic local micro-environmental immune status in hepatocellular carcinoma and cirrhotic tissues. The West Indian medical journal; 2006;55(6):403-408.